Loss of antigen expression has been described as resistance mechanism to various immunotherapies, e.g. Blinatumomab and Rituximab, for several B-cell neoplasms, but comprehensive studies on the frequency of CD22 loss after InO treatment in B-ALL are lacking [14]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.